• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer.

作者信息

Altundag Kadri

机构信息

MKA Breast Cancer Clinic, Tepe Prime, Cankaya, 06800, Ankara, Turkey.

出版信息

Med Oncol. 2024 Oct 14;41(11):279. doi: 10.1007/s12032-024-02515-1.

DOI:10.1007/s12032-024-02515-1
PMID:39400749
Abstract
摘要

相似文献

1
PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer.用于治疗三阴性乳腺癌的PI3K/AKT/mTOR抑制剂
Med Oncol. 2024 Oct 14;41(11):279. doi: 10.1007/s12032-024-02515-1.
2
PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer.用于激素受体阳性晚期乳腺癌的PI3K/AKT/mTOR抑制剂
Cancer Treat Rev. 2025 Jan;132:102861. doi: 10.1016/j.ctrv.2024.102861. Epub 2024 Nov 19.
3
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.PI3K/AKT/mTOR 信号通路：三阴性乳腺癌的重要驱动因子和治疗靶点。
Breast Cancer. 2024 Jul;31(4):539-551. doi: 10.1007/s12282-024-01567-5. Epub 2024 Apr 17.
4
Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.靶向抑制 PI3K/Akt/mTOR 信号通路：肉瘤治疗的潜力。
Mini Rev Med Chem. 2024;24(16):1496-1520. doi: 10.2174/0113895575270904231129062137.
5
A Perspective of PI3K/AKT/mTOR Pathway Inhibitors to Overcome Drug-resistance in Breast Cancer Therapy.PI3K/AKT/mTOR信号通路抑制剂克服乳腺癌治疗耐药性的研究进展
Curr Med Chem. 2025;32(10):1865-1873. doi: 10.2174/0109298673327425240815065221.
6
Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy.针对PI3K/AKT/mTOR通路进行乳腺癌治疗的策略进展
Biochem Pharmacol. 2025 Jun;236:116850. doi: 10.1016/j.bcp.2025.116850. Epub 2025 Mar 4.
7
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.儿科药物研发策略论坛：针对癌症患儿和青少年的 PI3-K、mTOR、AKT 和 GSK3β 抑制剂
Eur J Cancer. 2024 Aug;207:114145. doi: 10.1016/j.ejca.2024.114145. Epub 2024 Jun 8.
8
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.PI3K 和 MEK 抑制剂联合治疗可使 PIK3CA 突变性乳腺肉瘤样癌 PDX 模型获得持久缓解。
J Hematol Oncol. 2020 Feb 22;13(1):13. doi: 10.1186/s13045-020-0846-y.
9
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.PI3K/Akt/mTOR 抑制剂在癌症中的应用：从实验室到临床。
Semin Cancer Biol. 2019 Dec;59:125-132. doi: 10.1016/j.semcancer.2019.07.009. Epub 2019 Jul 16.
10
Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway.对前列腺癌细胞功能的评估突出了泛PI3K/mTOR抑制剂gedatolisib与PI3K/AKT/mTOR途径单节点抑制剂之间的差异。
Mol Oncol. 2025 Jan;19(1):225-247. doi: 10.1002/1878-0261.13703. Epub 2024 Aug 2.

引用本文的文献

1
Treatment strategies targeting the phosphoinositide 3-kinase/protein kinase B/mechanistic target of rapamycin pathway against triple-negative breast cancer.针对磷酸肌醇3激酶/蛋白激酶B/雷帕霉素作用机制靶点通路治疗三阴性乳腺癌的策略
World J Clin Oncol. 2025 May 24;16(5):104623. doi: 10.5306/wjco.v16.i5.104623.
2
Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.乳腺癌中PI3K/AKT/mTOR通路独特的mRNA表达谱及miRNA调控因子：对肿瘤进展和治疗靶点的见解
Front Oncol. 2025 Jan 9;14:1515387. doi: 10.3389/fonc.2024.1515387. eCollection 2024.

本文引用的文献

1
The treatment landscape of triple-negative breast cancer.三阴性乳腺癌的治疗现状。
Med Oncol. 2024 Aug 29;41(10):236. doi: 10.1007/s12032-024-02456-9.
2
PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.PI3K/AKT/mTOR 信号通路：三阴性乳腺癌的重要驱动因子和治疗靶点。
Breast Cancer. 2024 Jul;31(4):539-551. doi: 10.1007/s12282-024-01567-5. Epub 2024 Apr 17.
3
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.考潘利昔布在复发性或难治性惰性淋巴瘤中对磷酸肌醇 3-激酶的抑制作用。
J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4.